Disc Medicine, Inc. (NASDAQ:IRON) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Disc Medicine, Inc. (NASDAQ:IRON) have been given an average recommendation of “Moderate Buy” by the thirteen research firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eleven have assigned a buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $119.4545.

A number of analysts have issued reports on IRON shares. Wedbush reaffirmed an “outperform” rating on shares of Disc Medicine in a research note on Thursday, January 15th. UBS Group reissued an “overweight” rating on shares of Disc Medicine in a research report on Thursday, January 15th. National Bankshares set a $153.00 price objective on shares of Disc Medicine in a research report on Friday, October 17th. Truist Financial lifted their target price on shares of Disc Medicine from $86.00 to $114.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Finally, TD Cowen reiterated a “buy” rating on shares of Disc Medicine in a report on Friday, December 19th.

Disc Medicine Price Performance

NASDAQ:IRON opened at $79.72 on Friday. Disc Medicine has a one year low of $30.82 and a one year high of $99.50. The stock has a market cap of $3.01 billion, a PE ratio of -14.90 and a beta of 0.88. The company has a debt-to-equity ratio of 0.05, a quick ratio of 23.45 and a current ratio of 23.45. The stock has a 50 day moving average price of $81.92 and a 200 day moving average price of $74.83.

Disc Medicine (NASDAQ:IRON) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($1.77) EPS for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.29). Equities research analysts expect that Disc Medicine will post -4.07 EPS for the current fiscal year.

Insider Transactions at Disc Medicine

In other Disc Medicine news, insider William Jacob Savage sold 13,093 shares of Disc Medicine stock in a transaction on Monday, December 15th. The stock was sold at an average price of $91.22, for a total value of $1,194,343.46. Following the sale, the insider owned 75,702 shares in the company, valued at $6,905,536.44. The trade was a 14.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Kevin Bitterman sold 68,923 shares of the company’s stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $91.24, for a total value of $6,288,534.52. Following the completion of the transaction, the director directly owned 14,161 shares in the company, valued at approximately $1,292,049.64. This trade represents a 82.96% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 275,470 shares of company stock valued at $24,966,170 in the last ninety days. 3.64% of the stock is currently owned by corporate insiders.

Institutional Trading of Disc Medicine

Several institutional investors and hedge funds have recently bought and sold shares of IRON. Y Intercept Hong Kong Ltd lifted its stake in Disc Medicine by 361.4% during the third quarter. Y Intercept Hong Kong Ltd now owns 43,287 shares of the company’s stock worth $2,860,000 after purchasing an additional 33,905 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Disc Medicine by 11.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 843,616 shares of the company’s stock valued at $44,678,000 after buying an additional 84,278 shares during the period. Atle Fund Management AB lifted its stake in Disc Medicine by 85.3% during the 3rd quarter. Atle Fund Management AB now owns 45,690 shares of the company’s stock worth $3,019,000 after acquiring an additional 21,038 shares in the last quarter. Assenagon Asset Management S.A. acquired a new position in Disc Medicine during the 3rd quarter worth about $689,000. Finally, Sio Capital Management LLC boosted its holdings in Disc Medicine by 287.4% during the 2nd quarter. Sio Capital Management LLC now owns 284,787 shares of the company’s stock valued at $15,082,000 after acquiring an additional 211,276 shares during the period. 83.70% of the stock is currently owned by hedge funds and other institutional investors.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.